MedTrace Logo

PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer

NCT03927248 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-05-07

No results posted yet for this study

Summary

The primary objective of the pilot study is to determine activity of PAC-1 and nivolumab combination in subjects with metastatic renal cell carcinoma previously treated with immune checkpoint inhibitor therapy as assessed by objective response rate (ORR) using RECIST 1.1 criteria.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Nivolumab

See description in Arms/Groups section

Sponsors & Collaborators

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Peter Hurley, MD · HealthPartners Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-09-30
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927248 on ClinicalTrials.gov